Sunitinib, an orally available multitargeted receptor tyrosine kinases inhibitor, effectively induced growth arrest and apoptosis of acute myelogenous leukemia (AML) cells with gain of function mutation in fms-like tyrosine kinase 3 (FLT3) (FLT3-ITD) in vitro and in vivo. 1 This study found that sunitinib induced monocytic differentiation of AML cells irrespective of FLT3 gene status. For example, exposure of HL60 cells with the wild-type FLT3 and MOLM13 cells expressing FLT3-ITD to sunitinib increased levels of CD11b antigen, a marker of myeloid differentiation, on their cell surface (Figure 1a) . Sunitinib also increased levels of CD14 cell surface antigens and stimulated their endocytic capacity, as measured by the internalization of fluorescein isothiocyanate-labeled dextran (data not shown). Moreover, sunitinib stimulated the production of inflammatory cytokines, such as interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a) in AML cells (Figures 1b and c) , indicating monocytic differentiation of AML cells. Sunitinib-mediated monocytic differentiation was further confirmed by morphological change (Figure 1d differentiation was significantly potentiated in the presence of 1,25(OH) 2 D 3 , a known inducer of monocytic differentiation in leukemia cells (Figures 1a-c) .
2 Furthermore, 1,25(OH) 2 D 3 potentiated the ability of sunitinib to inhibit the clonogenic growth of AML cells (Figure 1e) .
CCAAT/enhancer binding protein-a (C/EBP-a) belongs to a family of nuclear transcription factor and is required for myeloid differentiation.
3 Sunitinib increased levels of C/EBP-a in association with downregulation of c-Myc, a negative regulator of differentiation, in MOLM13 and HL60 cells (Figure 2 ). Sunitinib might induce monocytic differentiation of AML cells through modulation of these transcription factors.
We next examine whether sunitinib affected the activity of normal hematopoietic cells in vivo. Treatment of C57BL/6 mice (n ¼ 5) with sunitinib (20 mg/kg, 5 days) significantly increased the population of CD14 þ mononuclear cells and CD8 þ T cells in their spleen and bone marrow (Table 1) . Also, sunitinib stimulated the production of IFN-g and TNF-a in their spleen mononuclear cells (Figure 3 ). These observations suggested that sunitinib activated the inflammatory cells in vivo.
Finally, we attempted to verify the molecular mechanisms by which sunitinib induced monocytic differentiation of hematopoietic cells. Notably, when AML cells were pre-incubated with anti-human TNF-a monoclonal antibody infliximab (100 ng/ml), sunitinib-induced expression of CD11b was almost completely blocked (Table 2) Letters to the Editor sunitinib (2.5-20 nM), which was not able to dephosphorylate FLT3 and its downstream signal pathways in MOLM13 and HL60 cells (data not shown). Sunitinib also induced the differentiation of U937 cells, which did not express FLT3 on their cell surface (data not shown). Thus, sunitinib-induced differentiation was probably independent of FLT3. Recently, erlotinib as well as gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR), induced growth arrest and differentiation of AML cells in vitro and in vivo, which was independent of EGFR signaling. 4, 5 Erlotinib and gefitinib could produce TNF-a, resulting in the differentiation of AML cells. Acute myelogenous leukemia cells were pre-incubated with antihuman tumor necrosis factor-a monoclonal antibody infliximab (100 ng/ml) for 1 h, and then exposed to various concentrations of sunitinib (2.5-20 nM). After 2 days, cells were harvested, and CD11b-expressing population was analyzed by flow cytometry.
